Clinical Trial Update: Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients [Phase 2]

View source ↗

Summary

Phase 2 trial of Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for chronic myeloid leukemia was terminated with results posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Antithymocyte Globulin (anti-thymocyte globulin)
• BUSULFAN (Busulfan)
• Fludarabine (Fludarabine)
• Imatinib mesylate (Imatinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Leukemia | Phase 2 | Status: TERMINATED | Results posted: 2011-11-07